4,814 Shares in PROCEPT BioRobotics Co. (NASDAQ:PRCT) Acquired by Counterpoint Mutual Funds LLC

Counterpoint Mutual Funds LLC bought a new position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) in the fourth quarter, Holdings Channel reports. The fund bought 4,814 shares of the company’s stock, valued at approximately $388,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Signaturefd LLC boosted its holdings in PROCEPT BioRobotics by 26.7% during the fourth quarter. Signaturefd LLC now owns 689 shares of the company’s stock worth $55,000 after buying an additional 145 shares in the last quarter. Cibc World Markets Corp purchased a new stake in shares of PROCEPT BioRobotics in the 4th quarter valued at approximately $336,000. Commonwealth Equity Services LLC purchased a new stake in shares of PROCEPT BioRobotics in the 4th quarter valued at approximately $213,000. Swiss National Bank lifted its position in shares of PROCEPT BioRobotics by 1.8% in the 4th quarter. Swiss National Bank now owns 97,100 shares of the company’s stock valued at $7,818,000 after acquiring an additional 1,700 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of PROCEPT BioRobotics by 187.1% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 49,126 shares of the company’s stock valued at $3,956,000 after acquiring an additional 32,015 shares in the last quarter. 89.46% of the stock is currently owned by institutional investors.

PROCEPT BioRobotics Trading Up 2.4 %

Shares of NASDAQ:PRCT opened at $59.03 on Tuesday. The firm has a fifty day moving average of $70.07 and a two-hundred day moving average of $79.05. The firm has a market capitalization of $3.24 billion, a P/E ratio of -30.27 and a beta of 1.05. PROCEPT BioRobotics Co. has a 12-month low of $45.56 and a 12-month high of $103.81. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The company had revenue of $68.24 million for the quarter, compared to analyst estimates of $66.79 million. On average, equities analysts expect that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on PRCT. Truist Financial restated a “buy” rating and issued a $90.00 price target (down previously from $105.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, February 26th. Morgan Stanley reduced their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. Finally, Wells Fargo & Company restated an “overweight” rating and issued a $112.00 price target on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, PROCEPT BioRobotics has an average rating of “Moderate Buy” and a consensus target price of $94.29.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).